{"transactions":[{"id":4622737,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2026-09-18T20:02:43.000Z","date":"2026-09-16","kind":"sale","planned":true,"acquired":false,"shares":568,"price":17.9,"value":10167.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted to the Reporting Person on December 15, 2025. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the Reporting Person on February 25, 2026, solely with the intent to cover taxes in connection with the vesting of the restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.10 to $19.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":19730,"source":{"system":"sec-edgar","filing":"0001628280-26-062705","document":"wk-form4_1789761760.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789545/000162828026062705/wk-form4_1789761760.xml","form_type":"4"}},{"id":728738,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2026-06-23T20:03:57.000Z","date":"2026-06-22","kind":"sale","planned":true,"acquired":false,"shares":1112,"price":17.99,"value":20004.88,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted to the Reporting Person on December 15, 2025. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the Reporting Person on February 25, 2026, solely with the intent to cover taxes in connection with the vesting of the restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.88 to $18.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":20298,"source":{"system":"sec-edgar","filing":"0001628280-26-044890","document":"wk-form4_1782245034.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000162828026044890/wk-form4_1782245034.xml","form_type":"4"}},{"id":964662,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-17T21:45:39.000Z","date":"2025-12-15","kind":"grant","planned":false,"acquired":true,"shares":57688,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This Option represents a right to purchase shares of the Issuer's Ordinary Shares and vests with respect to 1/48th of the Option on each monthly anniversary of December 15, 2025, subject to the Reporting Person remaining continuously employed by or providing services to the Issuer or its subsidiaries from December 15, 2025 through each such vesting date."}],"balance_after":57688,"derivative":{"exercise_price":13.21,"expiration_date":"2035-12-15","underlying":"Ordinary Shares","underlying_shares":57688},"source":{"system":"sec-edgar","filing":"0001628280-25-057681","document":"wk-form4_1766007936.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000162828025057681/wk-form4_1766007936.xml","form_type":"4"}},{"id":964661,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2025-12-17T21:45:39.000Z","date":"2025-12-15","kind":"grant","planned":false,"acquired":true,"shares":5000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents an award of Restricted Stock Units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Ordinary Shares. The RSUs shall vest in approximately equal three-month installments through the four-year anniversary of December 15, 2025, subject to the Reporting Person remaining continuously employed by or providing services to the Issuer or its subsidiaries from December 15, 2025 through each such vesting date."}],"balance_after":19422,"source":{"system":"sec-edgar","filing":"0001628280-25-057681","document":"wk-form4_1766007936.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000162828025057681/wk-form4_1766007936.xml","form_type":"4"}},{"id":964660,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2025-12-17T21:45:39.000Z","date":"2025-12-15","kind":"grant","planned":false,"acquired":true,"shares":14422,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents an award of Restricted Stock Units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Ordinary Shares. The RSUs shall vest in approximately equal three-month installments through the four-year anniversary of December 15, 2025, subject to the Reporting Person remaining continuously employed by or providing services to the Issuer or its subsidiaries from December 15, 2025 through each such vesting date."}],"balance_after":14422,"source":{"system":"sec-edgar","filing":"0001628280-25-057681","document":"wk-form4_1766007936.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000162828025057681/wk-form4_1766007936.xml","form_type":"4"}},{"id":1207880,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Head of Finance & Admin."}}],"security":"Common Stock","published_at":"2025-03-13T20:08:57.000Z","date":"2025-03-11","kind":"sale","planned":true,"acquired":false,"shares":1343,"price":11.38,"value":15283.34,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $11.25 to $11.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 109,054 unvested RSUs."}],"balance_after":122330,"source":{"system":"sec-edgar","filing":"0000950170-25-038731","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017025038731/ownership.xml","form_type":"4"}},{"id":1217567,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Head of Finance & Admin."}}],"security":"Common Stock","published_at":"2025-03-07T21:06:01.000Z","date":"2025-03-05","kind":"sale","planned":true,"acquired":false,"shares":917,"price":11.83,"value":10848.11,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 4, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $11.73 to $11.94, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 112,036 unvested RSUs."}],"balance_after":123673,"source":{"system":"sec-edgar","filing":"0000950170-25-035490","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017025035490/ownership.xml","form_type":"4"}},{"id":1263958,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Head of Finance & Admin."}}],"security":"Common Stock","published_at":"2025-02-18T22:09:41.000Z","date":"2025-02-18","kind":"sale","planned":true,"acquired":false,"shares":2488,"price":13.95,"value":34707.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on November 15, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $13.95 to $14.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 114,079 unvested RSUs."}],"balance_after":124590,"source":{"system":"sec-edgar","filing":"0000950170-25-022455","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017025022455/ownership.xml","form_type":"4"}},{"id":1335807,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Head of Finance & Admin."}}],"security":"Common Stock","published_at":"2024-12-12T01:40:49.000Z","date":"2024-12-11","kind":"sale","planned":true,"acquired":false,"shares":1455,"price":28.12,"value":40914.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $27.76 to $28.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 119,688 unvested RSUs."}],"balance_after":127078,"source":{"system":"sec-edgar","filing":"0000950170-24-135570","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024135570/ownership.xml","form_type":"4"}},{"id":1340572,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Head of Finance & Admin."}}],"security":"Stock option (right to buy)","published_at":"2024-12-06T21:05:14.000Z","date":"2024-12-04","kind":"grant","planned":false,"acquired":true,"shares":52300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on December 4, 2024. The shares underlying the option are scheduled to vest over four years in equal monthly installments through December 4, 2028."}],"balance_after":52300,"derivative":{"exercise_price":29.44,"expiration_date":"2034-12-03","underlying":"Common Stock","underlying_shares":52300},"source":{"system":"sec-edgar","filing":"0000950170-24-134075","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024134075/ownership.xml","form_type":"4"}},{"id":1340571,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Head of Finance & Admin."}}],"security":"Common Stock","published_at":"2024-12-06T21:05:14.000Z","date":"2024-12-04","kind":"grant","planned":false,"acquired":true,"shares":32700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of shares of Common Stock issuable under 32,700 restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on March 4, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 122,669 unvested RSUs."}],"balance_after":128533,"source":{"system":"sec-edgar","filing":"0000950170-24-134075","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024134075/ownership.xml","form_type":"4"}},{"id":1361899,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Head of Finance & Admin."}}],"security":"Common Stock","published_at":"2024-11-18T21:28:48.000Z","date":"2024-11-18","kind":"sale","planned":true,"acquired":false,"shares":2735,"price":28.2,"value":77127.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on November 15, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $28.00 to $28.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 89,969 unvested RSUs."}],"balance_after":95833,"source":{"system":"sec-edgar","filing":"0000950170-24-127992","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024127992/ownership.xml","form_type":"4"}},{"id":1402489,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Head of Finance & Admin."}}],"security":"Common Stock","published_at":"2024-09-19T20:52:03.000Z","date":"2024-09-18","kind":"sale","planned":true,"acquired":false,"shares":1390,"price":34.55,"value":48024.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on September 17, 2020. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $34.35 to $34.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 95,578 unvested RSUs."}],"balance_after":98568,"source":{"system":"sec-edgar","filing":"0000950170-24-108153","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024108153/ownership.xml","form_type":"4"}},{"id":1409831,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Head of Finance & Admin."}}],"security":"Common Stock","published_at":"2024-09-11T20:13:22.000Z","date":"2024-09-11","kind":"sale","planned":true,"acquired":false,"shares":1468,"price":31.89,"value":46814.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $31.59 to $32.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 98,445 unvested RSUs."}],"balance_after":99958,"source":{"system":"sec-edgar","filing":"0000950170-24-105515","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024105515/ownership.xml","form_type":"4"}},{"id":1410944,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Head of Finance & Admin."}}],"security":"Stock option (right to buy)","published_at":"2024-09-10T20:05:48.000Z","date":"2024-09-06","kind":"exercise","planned":false,"acquired":false,"shares":6552,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The option was granted on November 15, 2023. The shares underlying the option vest over four years in equal monthly installments through November 15, 2027."}],"balance_after":28394,"derivative":{"exercise_price":10.88,"expiration_date":"2033-11-14","underlying":"Common Stock","underlying_shares":6552},"source":{"system":"sec-edgar","filing":"0000950170-24-105123","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024105123/ownership.xml","form_type":"4"}},{"id":1410943,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Head of Finance & Admin."}}],"security":"Stock option (right to buy)","published_at":"2024-09-10T20:05:48.000Z","date":"2024-09-06","kind":"exercise","planned":false,"acquired":false,"shares":18750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The option was granted on December 9, 2022. The shares underlying the option vest over four years in equal monthly installments through December 10, 2026."}],"balance_after":26250,"derivative":{"exercise_price":10.72,"expiration_date":"2032-12-08","underlying":"Common Stock","underlying_shares":18750},"source":{"system":"sec-edgar","filing":"0000950170-24-105123","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024105123/ownership.xml","form_type":"4"}},{"id":1410942,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Head of Finance & Admin."}}],"security":"Stock option (right to buy)","published_at":"2024-09-10T20:05:48.000Z","date":"2024-09-06","kind":"exercise","planned":false,"acquired":false,"shares":29792,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The option was granted on July 11, 2022. The shares underlying the option vest over four years in equal monthly installments beginning on July 1, 2022."}],"balance_after":25208,"derivative":{"exercise_price":8.58,"expiration_date":"2032-07-10","underlying":"Common Stock","underlying_shares":29792},"source":{"system":"sec-edgar","filing":"0000950170-24-105123","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024105123/ownership.xml","form_type":"4"}},{"id":1410941,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Head of Finance & Admin."}}],"security":"Stock option (right to buy)","published_at":"2024-09-10T20:05:48.000Z","date":"2024-09-06","kind":"exercise","planned":false,"acquired":false,"shares":16696,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option was granted on December 10, 2021. The shares underlying the option vest over four years in equal monthly installments through December 10, 2025."}],"balance_after":8348,"derivative":{"exercise_price":13.12,"expiration_date":"2031-12-09","underlying":"Common Stock","underlying_shares":16696},"source":{"system":"sec-edgar","filing":"0000950170-24-105123","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024105123/ownership.xml","form_type":"4"}},{"id":1410940,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Head of Finance & Admin."}}],"security":"Stock option (right to buy)","published_at":"2024-09-10T20:05:48.000Z","date":"2024-09-06","kind":"exercise","planned":false,"acquired":false,"shares":34833,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option was granted on September 16, 2020. The shares underlying the option vest over four years in equal monthly installments through September 16, 2024."}],"balance_after":742,"derivative":{"exercise_price":19,"expiration_date":"2030-09-15","underlying":"Common Stock","underlying_shares":34833},"source":{"system":"sec-edgar","filing":"0000950170-24-105123","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024105123/ownership.xml","form_type":"4"}},{"id":1410939,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Head of Finance & Admin."}}],"security":"Stock option (right to buy)","published_at":"2024-09-10T20:05:48.000Z","date":"2024-09-06","kind":"exercise","planned":false,"acquired":false,"shares":3353,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option was granted on July 31, 2020. The shares underlying the option vest over four years in equal quarterly installments through July 31, 2024, provided that no shares shall vest prior to December 2, 2020."}],"balance_after":0,"derivative":{"exercise_price":5.54,"expiration_date":"2030-07-30","underlying":"Common Stock","underlying_shares":3353},"source":{"system":"sec-edgar","filing":"0000950170-24-105123","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024105123/ownership.xml","form_type":"4"}},{"id":1410938,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Head of Finance & Admin."}}],"security":"Stock option (right to buy)","published_at":"2024-09-10T20:05:48.000Z","date":"2024-09-06","kind":"exercise","planned":false,"acquired":false,"shares":6502,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option was granted on July 31, 2020. The shares underlying the option vest over four years in equal quarterly installments through July 31, 2024, provided that no shares shall vest prior to December 2, 2020."}],"balance_after":0,"derivative":{"exercise_price":5.54,"expiration_date":"2030-07-30","underlying":"Common Stock","underlying_shares":6502},"source":{"system":"sec-edgar","filing":"0000950170-24-105123","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024105123/ownership.xml","form_type":"4"}},{"id":1410937,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Head of Finance & Admin."}}],"security":"Common Stock","published_at":"2024-09-10T20:05:48.000Z","date":"2024-09-06","kind":"sale","planned":false,"acquired":false,"shares":1700,"price":32.63,"value":55471.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 101,426 unvested RSUs."}],"balance_after":101426,"source":{"system":"sec-edgar","filing":"0000950170-24-105123","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024105123/ownership.xml","form_type":"4"}},{"id":1410936,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Head of Finance & Admin."}}],"security":"Common Stock","published_at":"2024-09-10T20:05:48.000Z","date":"2024-09-06","kind":"sale","planned":false,"acquired":false,"shares":124374,"price":32.14,"value":3997380.36,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $31.62 to $32.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 101,426 unvested RSUs."}],"balance_after":103126,"source":{"system":"sec-edgar","filing":"0000950170-24-105123","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024105123/ownership.xml","form_type":"4"}},{"id":1410935,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Head of Finance & Admin."}}],"security":"Common Stock","published_at":"2024-09-10T20:05:48.000Z","date":"2024-09-06","kind":"exercise","planned":false,"acquired":true,"shares":6552,"price":10.88,"value":71285.76,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 101,426 unvested RSUs."}],"balance_after":227500,"source":{"system":"sec-edgar","filing":"0000950170-24-105123","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024105123/ownership.xml","form_type":"4"}},{"id":1410934,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Head of Finance & Admin."}}],"security":"Common Stock","published_at":"2024-09-10T20:05:48.000Z","date":"2024-09-06","kind":"exercise","planned":false,"acquired":true,"shares":18750,"price":10.72,"value":201000.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 101,426 unvested RSUs."}],"balance_after":220948,"source":{"system":"sec-edgar","filing":"0000950170-24-105123","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024105123/ownership.xml","form_type":"4"}},{"id":1410933,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Head of Finance & Admin."}}],"security":"Common Stock","published_at":"2024-09-10T20:05:48.000Z","date":"2024-09-06","kind":"exercise","planned":false,"acquired":true,"shares":29792,"price":8.58,"value":255615.36,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 101,426 unvested RSUs."}],"balance_after":202198,"source":{"system":"sec-edgar","filing":"0000950170-24-105123","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024105123/ownership.xml","form_type":"4"}},{"id":1410932,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Head of Finance & Admin."}}],"security":"Common Stock","published_at":"2024-09-10T20:05:48.000Z","date":"2024-09-06","kind":"exercise","planned":false,"acquired":true,"shares":16696,"price":13.12,"value":219051.52,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 101,426 unvested RSUs."}],"balance_after":172406,"source":{"system":"sec-edgar","filing":"0000950170-24-105123","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024105123/ownership.xml","form_type":"4"}},{"id":1410931,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Head of Finance & Admin."}}],"security":"Common Stock","published_at":"2024-09-10T20:05:48.000Z","date":"2024-09-06","kind":"exercise","planned":false,"acquired":true,"shares":34833,"price":19,"value":661827.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 101,426 unvested RSUs."}],"balance_after":155710,"source":{"system":"sec-edgar","filing":"0000950170-24-105123","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024105123/ownership.xml","form_type":"4"}},{"id":1410930,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Head of Finance & Admin."}}],"security":"Common Stock","published_at":"2024-09-10T20:05:48.000Z","date":"2024-09-06","kind":"exercise","planned":false,"acquired":true,"shares":3353,"price":5.54,"value":18575.62,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 101,426 unvested RSUs."}],"balance_after":120877,"source":{"system":"sec-edgar","filing":"0000950170-24-105123","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024105123/ownership.xml","form_type":"4"}},{"id":1410929,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Head of Finance & Admin."}}],"security":"Common Stock","published_at":"2024-09-10T20:05:48.000Z","date":"2024-09-06","kind":"exercise","planned":false,"acquired":true,"shares":6502,"price":5.54,"value":36021.08,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 101,426 unvested RSUs."}],"balance_after":117524,"source":{"system":"sec-edgar","filing":"0000950170-24-105123","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024105123/ownership.xml","form_type":"4"}},{"id":1427808,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Head of Finance & Admin."}}],"security":"Common Stock","published_at":"2024-08-20T20:28:01.000Z","date":"2024-08-19","kind":"sale","planned":true,"acquired":false,"shares":310,"price":46,"value":14260.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on November 15, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 that was entered into on January 25, 2024 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $45.53 to $46.45, inclusive."}],"balance_after":111022,"source":{"system":"sec-edgar","filing":"0000950170-24-099128","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024099128/ownership.xml","form_type":"4"}},{"id":1427807,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Head of Finance & Admin."}}],"security":"Common Stock","published_at":"2024-08-20T20:28:01.000Z","date":"2024-08-19","kind":"sale","planned":true,"acquired":false,"shares":2442,"price":45.01,"value":109914.42,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on November 15, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 that was entered into on January 25, 2024 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $44.51 to $45.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 101,426 unvested RSUs."}],"balance_after":111332,"source":{"system":"sec-edgar","filing":"0000950170-24-099128","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024099128/ownership.xml","form_type":"4"}},{"id":1483641,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Head of Finance & Admin."}}],"security":"Common Stock","published_at":"2024-06-11T23:28:44.000Z","date":"2024-06-11","kind":"sale","planned":true,"acquired":false,"shares":1331,"price":31.34,"value":41713.54,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $31.00 to $31.52, inclusive."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Includes 107,035 unvested RSUs."}],"balance_after":113774,"source":{"system":"sec-edgar","filing":"0000950170-24-072140","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024072140/ownership.xml","form_type":"4"}},{"id":1483640,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Head of Finance & Admin."}}],"security":"Common Stock","published_at":"2024-06-11T23:28:44.000Z","date":"2024-06-10","kind":"sale","planned":true,"acquired":false,"shares":1590,"price":30.23,"value":48065.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 11, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $30.08 to $30.47, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes of this Form 4."}],"balance_after":115105,"source":{"system":"sec-edgar","filing":"0000950170-24-072140","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024072140/ownership.xml","form_type":"4"}},{"id":1511662,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Head of Finance & Admin."}}],"security":"Common Stock","published_at":"2024-05-18T01:04:52.000Z","date":"2024-05-16","kind":"sale","planned":true,"acquired":false,"shares":462,"price":28.59,"value":13208.58,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on November 15, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 that was entered into on January 25, 2024 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $28.51 to $28.70, inclusive."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 110,016 unvested RSUs."}],"balance_after":116695,"source":{"system":"sec-edgar","filing":"0000950170-24-062077","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024062077/ownership.xml","form_type":"4"}},{"id":1511661,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Head of Finance & Admin."}}],"security":"Common Stock","published_at":"2024-05-18T01:04:52.000Z","date":"2024-05-16","kind":"sale","planned":true,"acquired":false,"shares":2126,"price":28.2,"value":59953.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on November 15, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 that was entered into on January 25, 2024 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $27.50 to $28.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes of this Form 4."}],"balance_after":117157,"source":{"system":"sec-edgar","filing":"0000950170-24-062077","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024062077/ownership.xml","form_type":"4"}},{"id":1581407,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Head of Finance & Admin."}}],"security":"Stock option (right to buy)","published_at":"2024-03-13T01:57:40.000Z","date":"2024-03-08","kind":"exercise","planned":true,"acquired":false,"shares":17333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The option was granted on July 31, 2020, with 100% of the option to vest upon the clearance date of an IND application submitted to the FDA by the Company with respect to one of its product candidates. On July 5, 2022, in connection with the clearance by the FDA of the Company's IND application for DYNE-251, the Compensation Committee determined that the performance condition had been achieved."}],"balance_after":0,"derivative":{"exercise_price":5.54,"expiration_date":"2030-07-30","underlying":"Common Stock","underlying_shares":17333},"source":{"system":"sec-edgar","filing":"0000950170-24-030482","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024030482/ownership.xml","form_type":"4"}},{"id":1581406,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Head of Finance & Admin."}}],"security":"Stock option (right to buy)","published_at":"2024-03-13T01:57:40.000Z","date":"2024-03-08","kind":"exercise","planned":true,"acquired":false,"shares":68919,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The option was granted on July 31, 2020. The shares underlying the option vest over four years in equal quarterly installments through July 31, 2024 provided that no shares shall vest prior to December 2, 2020."}],"balance_after":9855,"derivative":{"exercise_price":5.54,"expiration_date":"2030-07-30","underlying":"Common Stock","underlying_shares":68919},"source":{"system":"sec-edgar","filing":"0000950170-24-030482","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024030482/ownership.xml","form_type":"4"}},{"id":1581405,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Head of Finance & Admin."}}],"security":"Common Stock","published_at":"2024-03-13T01:57:40.000Z","date":"2024-03-11","kind":"sale","planned":true,"acquired":false,"shares":1590,"price":24.99,"value":39734.1,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F6","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 11, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $24.83 to $25.23, inclusive."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F8","text":"Includes 115,624 unvested RSUs."}],"balance_after":119283,"source":{"system":"sec-edgar","filing":"0000950170-24-030482","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024030482/ownership.xml","form_type":"4"}},{"id":1581404,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Head of Finance & Admin."}}],"security":"Common Stock","published_at":"2024-03-13T01:57:40.000Z","date":"2024-03-11","kind":"sale","planned":true,"acquired":false,"shares":1082,"price":25.7,"value":27807.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.50 to $26.09, inclusive."}],"balance_after":120873,"source":{"system":"sec-edgar","filing":"0000950170-24-030482","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024030482/ownership.xml","form_type":"4"}},{"id":1581403,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Head of Finance & Admin."}}],"security":"Common Stock","published_at":"2024-03-13T01:57:40.000Z","date":"2024-03-08","kind":"sale","planned":true,"acquired":false,"shares":289,"price":27.33,"value":7898.37,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $27.27 to $27.39, inclusive."}],"balance_after":121955,"source":{"system":"sec-edgar","filing":"0000950170-24-030482","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024030482/ownership.xml","form_type":"4"}},{"id":1581402,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Head of Finance & Admin."}}],"security":"Common Stock","published_at":"2024-03-13T01:57:40.000Z","date":"2024-03-08","kind":"sale","planned":true,"acquired":false,"shares":55208,"price":26.72,"value":1475157.76,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.20 to $27.15, inclusive."}],"balance_after":122244,"source":{"system":"sec-edgar","filing":"0000950170-24-030482","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024030482/ownership.xml","form_type":"4"}},{"id":1581401,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Head of Finance & Admin."}}],"security":"Common Stock","published_at":"2024-03-13T01:57:40.000Z","date":"2024-03-08","kind":"sale","planned":true,"acquired":false,"shares":30755,"price":25.31,"value":778409.05,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.20 to $26.19, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Form 4."}],"balance_after":177452,"source":{"system":"sec-edgar","filing":"0000950170-24-030482","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024030482/ownership.xml","form_type":"4"}},{"id":1581400,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Head of Finance & Admin."}}],"security":"Common Stock","published_at":"2024-03-13T01:57:40.000Z","date":"2024-03-08","kind":"exercise","planned":true,"acquired":true,"shares":17333,"price":5.54,"value":96024.82,"ownership":{"direct":true},"balance_after":208207,"source":{"system":"sec-edgar","filing":"0000950170-24-030482","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024030482/ownership.xml","form_type":"4"}},{"id":1581399,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Head of Finance & Admin."}}],"security":"Common Stock","published_at":"2024-03-13T01:57:40.000Z","date":"2024-03-08","kind":"exercise","planned":true,"acquired":true,"shares":68919,"price":5.54,"value":381811.26,"ownership":{"direct":true},"balance_after":190874,"source":{"system":"sec-edgar","filing":"0000950170-24-030482","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024030482/ownership.xml","form_type":"4"}},{"id":1584364,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Head of Finance & Admin."}}],"security":"Common Stock","published_at":"2024-03-12T01:45:41.000Z","date":"2024-03-07","kind":"sale","planned":true,"acquired":false,"shares":2273,"price":25.85,"value":58757.05,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on November 15, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.84 to $26.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 118,605 unvested RSUs."}],"balance_after":121955,"source":{"system":"sec-edgar","filing":"0000950170-24-029603","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024029603/ownership.xml","form_type":"4"}},{"id":1607442,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Head of Finance & Admin."}}],"security":"Stock option (right to buy)","published_at":"2024-03-02T02:37:15.000Z","date":"2024-03-01","kind":"exercise","planned":true,"acquired":false,"shares":9311,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option was granted on January 6, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on December 2, 2020 and the remaining shares vesting in equal quarterly installments thereafter."}],"balance_after":0,"derivative":{"exercise_price":1.03,"expiration_date":"2030-01-05","underlying":"Common Stock","underlying_shares":9311},"source":{"system":"sec-edgar","filing":"0000950170-24-024298","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024024298/ownership.xml","form_type":"4"}},{"id":1607441,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Head of Finance & Admin."}}],"security":"Stock option (right to buy)","published_at":"2024-03-02T02:37:15.000Z","date":"2024-02-29","kind":"exercise","planned":true,"acquired":false,"shares":3429,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option was granted on January 6, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on December 2, 2020 and the remaining shares vesting in equal quarterly installments thereafter."}],"balance_after":9311,"derivative":{"exercise_price":1.03,"expiration_date":"2030-01-05","underlying":"Common Stock","underlying_shares":3429},"source":{"system":"sec-edgar","filing":"0000950170-24-024298","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024024298/ownership.xml","form_type":"4"}},{"id":1607440,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Head of Finance & Admin."}}],"security":"Common Stock","published_at":"2024-03-02T02:37:15.000Z","date":"2024-03-01","kind":"sale","planned":true,"acquired":false,"shares":564,"price":28.65,"value":16158.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 11, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $28.55 to $28.83, inclusive."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 118,605 unvested RSUs."}],"balance_after":124228,"source":{"system":"sec-edgar","filing":"0000950170-24-024298","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024024298/ownership.xml","form_type":"4"}},{"id":1607439,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Head of Finance & Admin."}}],"security":"Common Stock","published_at":"2024-03-02T02:37:15.000Z","date":"2024-03-01","kind":"sale","planned":true,"acquired":false,"shares":8747,"price":28.22,"value":246840.34,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 11, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $27.50 to $28.48, inclusive."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 118,605 unvested RSUs."}],"balance_after":124792,"source":{"system":"sec-edgar","filing":"0000950170-24-024298","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024024298/ownership.xml","form_type":"4"}},{"id":1607438,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Head of Finance & Admin."}}],"security":"Common Stock","published_at":"2024-03-02T02:37:15.000Z","date":"2024-03-01","kind":"exercise","planned":true,"acquired":true,"shares":9311,"price":1.03,"value":9590.33,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 118,605 unvested RSUs."}],"balance_after":133539,"source":{"system":"sec-edgar","filing":"0000950170-24-024298","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024024298/ownership.xml","form_type":"4"}},{"id":1607437,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Head of Finance & Admin."}}],"security":"Common Stock","published_at":"2024-03-02T02:37:15.000Z","date":"2024-02-29","kind":"sale","planned":true,"acquired":false,"shares":3429,"price":27.5,"value":94297.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 11, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $27.50 to $27.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 118,605 unvested RSUs."}],"balance_after":124228,"source":{"system":"sec-edgar","filing":"0000950170-24-024298","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024024298/ownership.xml","form_type":"4"}},{"id":1607436,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Head of Finance & Admin."}}],"security":"Common Stock","published_at":"2024-03-02T02:37:15.000Z","date":"2024-02-29","kind":"exercise","planned":true,"acquired":true,"shares":3429,"price":1.03,"value":3531.87,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 118,605 unvested RSUs."}],"balance_after":127657,"source":{"system":"sec-edgar","filing":"0000950170-24-024298","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024024298/ownership.xml","form_type":"4"}},{"id":1669736,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Head of Finance & Admin."}}],"security":"Stock option (right to buy)","published_at":"2024-01-27T00:47:53.000Z","date":"2024-01-26","kind":"exercise","planned":true,"acquired":false,"shares":13000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option was granted on January 6, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on December 2, 2020 and the remaining shares vesting in equal quarterly installments thereafter."}],"balance_after":12740,"derivative":{"exercise_price":1.03,"expiration_date":"2030-01-05","underlying":"Common Stock","underlying_shares":13000},"source":{"system":"sec-edgar","filing":"0000950170-24-008061","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024008061/ownership.xml","form_type":"4"}},{"id":1669735,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Head of Finance & Admin."}}],"security":"Common Stock","published_at":"2024-01-27T00:47:53.000Z","date":"2024-01-26","kind":"sale","planned":true,"acquired":false,"shares":13000,"price":24.34,"value":316420.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 11, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $24.00 to $25.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 124,213 unvested RSUs."}],"balance_after":124228,"source":{"system":"sec-edgar","filing":"0000950170-24-008061","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024008061/ownership.xml","form_type":"4"}},{"id":1669734,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Head of Finance & Admin."}}],"security":"Common Stock","published_at":"2024-01-27T00:47:53.000Z","date":"2024-01-26","kind":"exercise","planned":true,"acquired":true,"shares":13000,"price":1.03,"value":13390.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 124,213 unvested RSUs."}],"balance_after":137228,"source":{"system":"sec-edgar","filing":"0000950170-24-008061","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024008061/ownership.xml","form_type":"4"}},{"id":1688096,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Head of Finance & Admin."}}],"security":"Stock option (right to buy)","published_at":"2024-01-05T02:46:58.000Z","date":"2024-01-03","kind":"exercise","planned":true,"acquired":false,"shares":13000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option was granted on January 6, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on December 2, 2020 and the remaining shares vesting in equal quarterly installments thereafter."}],"balance_after":25740,"derivative":{"exercise_price":1.03,"expiration_date":"2030-01-05","underlying":"Common Stock","underlying_shares":13000},"source":{"system":"sec-edgar","filing":"0000950170-24-002277","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024002277/ownership.xml","form_type":"4"}},{"id":1688095,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Head of Finance & Admin."}}],"security":"Common Stock","published_at":"2024-01-05T02:46:58.000Z","date":"2024-01-03","kind":"sale","planned":true,"acquired":false,"shares":13000,"price":18.81,"value":244530.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 11, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.50 to $19.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 124,213 unvested RSUs."}],"balance_after":124228,"source":{"system":"sec-edgar","filing":"0000950170-24-002277","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024002277/ownership.xml","form_type":"4"}},{"id":1688094,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Head of Finance & Admin."}}],"security":"Common Stock","published_at":"2024-01-05T02:46:58.000Z","date":"2024-01-03","kind":"exercise","planned":true,"acquired":true,"shares":13000,"price":1.03,"value":13390.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 124,213 unvested RSUs."}],"balance_after":137228,"source":{"system":"sec-edgar","filing":"0000950170-24-002277","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024002277/ownership.xml","form_type":"4"}},{"id":1711093,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-12-14T21:59:25.000Z","date":"2023-12-14","kind":"sale","planned":true,"acquired":false,"shares":2376,"price":12.02,"value":28559.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 11, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $12.00 to $12.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4."}],"balance_after":124228,"source":{"system":"sec-edgar","filing":"0001209191-23-058666","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919123058666/doc4.xml","form_type":"4"}},{"id":1714461,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-12-12T22:35:13.000Z","date":"2023-12-11","kind":"sale","planned":false,"acquired":false,"shares":1380,"price":10.72,"value":14793.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $10.72 to $10.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 124,213 unvested RSUs."}],"balance_after":126604,"source":{"system":"sec-edgar","filing":"0001209191-23-058332","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919123058332/doc4.xml","form_type":"4"}},{"id":1720173,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-12-06T23:13:25.000Z","date":"2023-12-06","kind":"sale","planned":true,"acquired":false,"shares":1872,"price":12.01,"value":22482.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 11, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $12.00 to $12.04, inclusive."}],"balance_after":127984,"source":{"system":"sec-edgar","filing":"0001209191-23-057671","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919123057671/doc4.xml","form_type":"4"}},{"id":1720172,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-12-06T23:13:25.000Z","date":"2023-12-04","kind":"sale","planned":true,"acquired":false,"shares":681,"price":12.01,"value":8178.81,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 11, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $12.00 to $12.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4."}],"balance_after":129856,"source":{"system":"sec-edgar","filing":"0001209191-23-057671","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919123057671/doc4.xml","form_type":"4"}},{"id":1739243,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2023-11-16T21:35:22.000Z","date":"2023-11-15","kind":"grant","planned":false,"acquired":true,"shares":34946,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on November 15, 2023. The shares underlying the option are scheduled to vest over four years in equal monthly installments through November 15, 2027."}],"balance_after":34946,"derivative":{"exercise_price":10.88,"expiration_date":"2033-11-14","underlying":"Common Stock","underlying_shares":34946},"source":{"system":"sec-edgar","filing":"0001209191-23-055533","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919123055533/doc4.xml","form_type":"4"}},{"id":1739242,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-11-16T21:35:22.000Z","date":"2023-11-15","kind":"grant","planned":false,"acquired":true,"shares":89742,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of shares of Common Stock issuable under 89,742 restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on February 15, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 127,193 unvested RSUs."}],"balance_after":130537,"source":{"system":"sec-edgar","filing":"0001209191-23-055533","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919123055533/doc4.xml","form_type":"4"}},{"id":1776300,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-09-20T20:49:38.000Z","date":"2023-09-18","kind":"sale","planned":false,"acquired":false,"shares":1290,"price":9.41,"value":12138.9,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on September 17, 2020. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 37,451 unvested RSUs."}],"balance_after":40795,"source":{"system":"sec-edgar","filing":"0001209191-23-050174","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919123050174/doc4.xml","form_type":"4"}},{"id":1782170,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-09-13T23:53:43.000Z","date":"2023-09-12","kind":"sale","planned":false,"acquired":false,"shares":1397,"price":10.41,"value":14542.77,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $10.07 to $10.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 40,317 unvested RSUs."}],"balance_after":42085,"source":{"system":"sec-edgar","filing":"0001209191-23-049361","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919123049361/doc4.xml","form_type":"4"}},{"id":1854583,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2023-06-15T21:46:17.000Z","date":"2023-06-13","kind":"exercise","planned":false,"acquired":false,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option was granted on January 6, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on December 2, 2020 and the remaining shares vesting in equal quarterly installments thereafter."}],"balance_after":38740,"derivative":{"exercise_price":1.03,"expiration_date":"2030-01-05","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-23-037487","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919123037487/doc4.xml","form_type":"4"}},{"id":1854582,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-06-15T21:46:17.000Z","date":"2023-06-15","kind":"sale","planned":false,"acquired":false,"shares":10000,"price":12.03,"value":120300.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $12.00 to $12.16, inclusive."}],"balance_after":43482,"source":{"system":"sec-edgar","filing":"0001209191-23-037487","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919123037487/doc4.xml","form_type":"4"}},{"id":1854581,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-06-15T21:46:17.000Z","date":"2023-06-13","kind":"sale","planned":false,"acquired":false,"shares":40000,"price":12.89,"value":515600.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $12.75 to $13.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) of this Form 4."}],"balance_after":53482,"source":{"system":"sec-edgar","filing":"0001209191-23-037487","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919123037487/doc4.xml","form_type":"4"}},{"id":1854580,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-06-15T21:46:17.000Z","date":"2023-06-13","kind":"exercise","planned":false,"acquired":true,"shares":40000,"price":1.03,"value":41200.0,"ownership":{"direct":true},"balance_after":93482,"source":{"system":"sec-edgar","filing":"0001209191-23-037487","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919123037487/doc4.xml","form_type":"4"}},{"id":1854579,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-06-15T21:46:17.000Z","date":"2023-06-13","kind":"sale","planned":false,"acquired":false,"shares":1390,"price":12.43,"value":17277.7,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 43,297 unvested RSUs."}],"balance_after":53482,"source":{"system":"sec-edgar","filing":"0001209191-23-037487","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919123037487/doc4.xml","form_type":"4"}},{"id":1952356,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-03-15T21:51:13.000Z","date":"2023-03-14","kind":"sale","acquired":false,"shares":1311,"price":13.33,"value":17475.63,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 46,277 unvested RSUs."}],"balance_after":54872,"source":{"system":"sec-edgar","filing":"0001209191-23-018982","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919123018982/doc4.xml","form_type":"4"}},{"id":2088166,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2022-12-13T22:06:31.000Z","date":"2022-12-09","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on December 9, 2022. The shares underlying the option are scheduled to vest over four years in equal monthly installments through December 10, 2026."}],"balance_after":45000,"derivative":{"exercise_price":10.72,"expiration_date":"2032-12-08","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001209191-22-060975","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919122060975/doc4.xml","form_type":"4"}},{"id":2088165,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2022-12-13T22:06:31.000Z","date":"2022-12-12","kind":"sale","acquired":false,"shares":312,"price":10.87,"value":3391.44,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 49,257 unvested RSUs."}],"balance_after":56183,"source":{"system":"sec-edgar","filing":"0001209191-22-060975","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919122060975/doc4.xml","form_type":"4"}},{"id":2088164,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2022-12-13T22:06:31.000Z","date":"2022-12-09","kind":"grant","acquired":true,"shares":31000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of shares of Common Stock issuable under 31,000 restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on March 10, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 50,300 unvested RSUs."}],"balance_after":56495,"source":{"system":"sec-edgar","filing":"0001209191-22-060975","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919122060975/doc4.xml","form_type":"4"}},{"id":2153527,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2022-09-21T20:09:27.000Z","date":"2022-09-20","kind":"disposition_to_issuer","acquired":false,"shares":840,"price":13.7,"value":11508.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on September 17, 2020. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price that represents the price of all shares sold by a broker on September 20, 2022 to satisfy tax withholding obligations. These shares were sold in multiple transactions at prices within the range of $13.70 to $13.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 19,300 unvested RSUs."}],"balance_after":25495,"source":{"system":"sec-edgar","filing":"0001209191-22-050893","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919122050893/doc4.xml","form_type":"4"}},{"id":2158511,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2022-09-15T21:30:18.000Z","date":"2022-09-15","kind":"disposition_to_issuer","acquired":false,"shares":326,"price":14.05,"value":4580.3,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price that represents the price of all shares sold by a broker on September 15, 2022 to satisfy tax withholding obligations. These shares were sold in multiple transactions at prices within the range of $14.05 to $14.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 22,166 unvested RSUs."}],"balance_after":26335,"source":{"system":"sec-edgar","filing":"0001209191-22-050127","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919122050127/doc4.xml","form_type":"4"}},{"id":2208092,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2022-07-13T20:38:51.000Z","date":"2022-07-11","kind":"grant","acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on July 11, 2022. The shares underlying the option are scheduled to vest over four years in equal monthly installments from July 1, 2022."}],"balance_after":55000,"derivative":{"exercise_price":8.58,"expiration_date":"2032-07-10","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001209191-22-042058","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919122042058/doc4.xml","form_type":"4"}},{"id":2212183,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2022-07-06T22:23:07.000Z","date":"2022-07-05","kind":"grant","acquired":true,"shares":17333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on July 31, 2020, with 100% of the option to vest upon the clearance date of an Investigational New Drug (IND) application submitted to the U.S. Food and Drug Administration (FDA) by the Company with respect to one of its product candidates. On July 5, 2022, in connection with the clearance by the FDA of the Company's IND application for DYNE-251, the Compensation Committee determined that the performance condition had been achieved."}],"balance_after":17333,"derivative":{"exercise_price":5.54,"expiration_date":"2030-07-30","underlying":"Common Stock","underlying_shares":17333},"source":{"system":"sec-edgar","filing":"0001209191-22-041342","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919122041342/doc4.xml","form_type":"4"}},{"id":2231586,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2022-06-16T00:05:38.000Z","date":"2022-06-14","kind":"disposition_to_issuer","acquired":false,"shares":333,"price":4.95,"value":1648.35,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 23,209 unvested RSUs."}],"balance_after":26661,"source":{"system":"sec-edgar","filing":"0001209191-22-037153","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919122037153/doc4.xml","form_type":"4"}},{"id":2335683,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2022-03-14T21:09:36.000Z","date":"2022-03-11","kind":"sale","acquired":false,"shares":308,"price":8.73,"value":2688.84,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price that represents the price of all shares sold by a broker on March 11, 2022 to satisfy tax withholding obligations. These shares were sold in multiple transactions at prices within the range of $8.65 to $8.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 24,252 unvested RSUs."}],"balance_after":26994,"source":{"system":"sec-edgar","filing":"0001209191-22-018537","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919122018537/doc4.xml","form_type":"4"}},{"id":2473657,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2021-12-14T21:23:56.000Z","date":"2021-12-10","kind":"grant","acquired":true,"shares":25044,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on December 10, 2021. The shares underlying the option are scheduled to vest over four years in equal monthly installments through December 10, 2025."}],"balance_after":25044,"derivative":{"exercise_price":13.12,"expiration_date":"2031-12-09","underlying":"Common Stock","underlying_shares":25044},"source":{"system":"sec-edgar","filing":"0001209191-21-069428","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919121069428/doc4.xml","form_type":"4"}},{"id":2473656,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-12-14T21:23:56.000Z","date":"2021-12-10","kind":"grant","acquired":true,"shares":16696,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of shares of Common Stock issuable under 16,696 restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on March 10, 2022."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 25,295 unvested RSUs. Each unvested RSU represents the right to receive one share of Common Stock upon vesting."}],"balance_after":27302,"source":{"system":"sec-edgar","filing":"0001209191-21-069428","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919121069428/doc4.xml","form_type":"4"}},{"id":2562154,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-09-23T00:03:25.000Z","date":"2021-09-21","kind":"sale","acquired":false,"shares":492,"price":16.11,"value":7926.12,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on September 17, 2020. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price that represents the price of all shares sold by a broker on September 21, 2021 on behalf of a group of employees of the issuer to satisfy tax withholding obligations. These shares were sold in multiple transactions at prices within the range of $15.87 to $16.36, inclusive."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 8,599 unvested RSUs."}],"balance_after":10606,"source":{"system":"sec-edgar","filing":"0001209191-21-057326","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919121057326/doc4.xml","form_type":"4"}},{"id":2562153,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-09-23T00:03:25.000Z","date":"2021-09-20","kind":"sale","acquired":false,"shares":367,"price":15.61,"value":5728.87,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on September 17, 2020. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price that represents the price of all shares sold by a broker on September 20, 2021 on behalf of a group of employees of the issuer to satisfy tax withholding obligations. These shares were sold in multiple transactions at prices within the range of $15.22 to $16.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in footnote (2) and (4) of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 8,599 unvested RSUs."}],"balance_after":11098,"source":{"system":"sec-edgar","filing":"0001209191-21-057326","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919121057326/doc4.xml","form_type":"4"}},{"id":3027142,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2020-09-18T21:10:28.000Z","date":"2020-09-16","kind":"grant","acquired":true,"shares":35575,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on September 16, 2020. The shares underlying the option are scheduled to vest over four years in equal monthly installments through September 16, 2024."}],"balance_after":35575,"derivative":{"exercise_price":19,"expiration_date":"2030-09-15","underlying":"Common Stock","underlying_shares":35575},"source":{"system":"sec-edgar","filing":"0000899243-20-025735","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000089924320025735/doc4.xml","form_type":"4"}},{"id":3027141,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":35932,"kind":"person","name":"Scalzo Richard William","position":1,"cik":"0001789545","reported_name":"Scalzo Richard William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-09-18T21:10:28.000Z","date":"2020-09-17","kind":"grant","acquired":true,"shares":11465,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of shares of Common Stock issuable under 11,465 restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal annual installments over four years with the first installment vesting on September 17, 2021."}],"balance_after":11465,"source":{"system":"sec-edgar","filing":"0000899243-20-025735","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000089924320025735/doc4.xml","form_type":"4"}}]}